Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.02
Percentage change -0.06	%

Peers: VRTX REGN NBIX SRPT BMRN RARE FOLD IONS BLUE TVRD

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-2.65	Insider Own	23.36%	Shs Outstand	94.87M	Perf Week	17.99%
Market Cap	3.25B	Forward P/E	-	EPS next Y	-1.53	Insider Trans	-8.19%	Shs Float	72.77M	Perf Month	15.25%
Income	-264.16M	PEG	-	EPS next Q	-0.68	Inst Own	96.85%	Short Float	20.90%	Perf Quarter	-4.92%
Sales	0.00M	P/S	-	EPS this Y	-7.23%	Inst Trans	3.05%	Short Ratio	11.97	Perf Half Y	-13.08%
Book/sh	3.29	P/B	10.40	EPS next Y	42.18%	ROA	-78.29%	Short Interest	15.21M	Perf Year	249.29%
Cash/sh	3.84	P/C	8.92	EPS next 5Y	54.53%	ROE	-106.71%	52W Range	6.76 - 46.98	Perf YTD	-20.80%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-5.90%	ROI	-71.40%	52W High	-27.14%	Beta	0.29
Dividend TTM	-	Quick Ratio	10.25	Sales past 5Y	-	Gross Margin	-	52W Low	406.36%	ATR (14)	1.90
Dividend Ex-Date	-	Current Ratio	10.25	EPS Y/Y TTM	-20.30%	Oper. Margin	-	RSI (14)	62.27	Volatility	5.09% 3.73%
Employees	196	Debt/Eq	0.20	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	49.67
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	-12.68%	Payout	-	Rel Volume	1.44	Prev Close	34.25
Sales Surprise	-	EPS Surprise	-1.41%	Sales Q/Q	-	Earnings	May 14 BMO	Avg Volume	1.27M	Price	34.23
SMA20	10.86%	SMA50	11.55%	SMA200	12.55%	Trades		Volume	1,826,606	Change	-0.06%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-26-24	Reiterated	H.C. Wainwright	Buy	$40 → $50
Oct-07-24	Reiterated	H.C. Wainwright	Buy	$30 → $35
Mar-28-24	Initiated	Raymond James	Strong Buy	$30
Oct-25-23	Upgrade	Jefferies	Hold → Buy	$20
Apr-03-23	Resumed	Piper Sandler	Overweight	$26
Sep-19-22	Resumed	H.C. Wainwright	Buy	$30
Jul-12-22	Initiated	Truist	Buy	$20
Mar-23-22	Initiated	H.C. Wainwright	Buy	$24
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$52 → $28
Nov-19-21	Initiated	Piper Sandler	Overweight	$56
Apr-26-21	Resumed	Credit Suisse	Outperform	$65
Jan-11-21	Initiated	Credit Suisse	Outperform	$65
Jan-06-21	Initiated	JP Morgan	Overweight	$59
Mar-12-20	Initiated	Robert W. Baird	Outperform	$35

Show Previous Ratings

Jun-05-25 08:00AM	Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (Business Wire) +11.13%
Jun-02-25 08:00AM	Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager (Business Wire)
May-28-25 08:00AM	Scholar Rock to Present at the Jefferies Global Healthcare Conference (Business Wire) -5.28%
May-16-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-15-25 03:10AM	Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings Call Highlights: Strong Progress and ... (GuruFocus.com)
01:39AM	Loading…
01:39AM	Q1 2025 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents)
May-14-25 07:00AM	Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress (Business Wire)
May-13-25 09:24AM	What To Expect From Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings (GuruFocus.com)
May-07-25 08:00AM	Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025 (Business Wire)
May-06-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.01%
Apr-28-25 07:08PM	Why Scholar Rock Stock Took a Knock on Monday (Motley Fool)
06:50AM	Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth (Business Wire)
Apr-23-25 06:34PM	Why Scholar Rock Holding Stock Topped the Market Today (Motley Fool) +5.72%
Apr-21-25 04:37PM	Scholar Rock Holding Corp (SRRK) Q4 2024 Earnings Call Highlights: Clinical Success and ... (GuruFocus.com) +6.14%
Apr-19-25 05:30AM	ClearBridge Small Cap Strategy Q1 2025 Commentary (Seeking Alpha)
04:15PM	Loading…
Apr-18-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-25 11:07AM	Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade (Seeking Alpha)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-25-25 07:30AM	FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy (Business Wire)
Mar-17-25 08:31AM	Scholar Rock SMA drug shows muscle function benefit (Clinical Trials Arena)
Mar-16-25 07:00PM	Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference (Business Wire)
Mar-14-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 11:16PM	Q4 2024 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents) +7.95%
07:00AM	Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress (Business Wire)
Feb-26-25 07:24AM	Earnings To Watch: Scholar Rock Holding Corp (SRRK) Reports Q4 2024 Result (GuruFocus.com)
Feb-25-25 04:15PM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Feb-24-25 01:10PM	Is Scholar Rock Holding (SRRK) One of the Oversold Biotech Stocks to Buy Now? (Insider Monkey)
Feb-21-25 08:00AM	Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (Business Wire)
Feb-14-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	Loading…
Feb-10-25 08:00AM	Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025 (Business Wire)
Jan-29-25 08:05AM	Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) (Business Wire)
08:00AM	Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition (Business Wire)
Jan-17-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-13-25 06:48PM	Heres Why Scholar Rock Holding Corporation (SRRK) Is Skyrocketing (Insider Monkey) +5.21%
Jan-08-25 04:00PM	Scholar Rock Highlights 2025 Strategic Priorities (Business Wire)
Jan-02-25 08:00AM	Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-13-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-04-24 12:36PM	Why Is Scholar Rock Holding Corporation (SRRK) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-25-24 11:51AM	Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study (Benzinga) +26.07%
06:13AM	Biohaven muscle drug misses goal of SMA study, but advances in obesity (BioPharma Dive)
Nov-15-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-13-24 02:08AM	Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 07:00AM	Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress (Business Wire) -5.29%
Nov-11-24 07:07AM	Scholar Rock Holding Corp (SRRK) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 08:00AM	Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin (Business Wire)
Nov-01-24 08:00AM	Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (Business Wire)
Oct-31-24 04:00PM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire) -5.14%
08:00AM	Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting (Business Wire)
Oct-22-24 08:00AM	Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering (Business Wire)
Oct-21-24 09:55AM	Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross? (Zacks)
Oct-18-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-11-24 06:30PM	PBF Energy, Gold Reserve, and More Stocks See Action From Activist Investors (Barrons.com) +7.58%
Oct-09-24 05:34PM	Scholar Rock Holding Corp (SRRK) Q2 2024 Earnings Call Highlights: Advancing Key Milestones in ... (GuruFocus.com) -5.83% -5.87%
05:38AM	Here's Why Everybody's Talking About Scholar Rock Right Now (Motley Fool)
Oct-08-24 11:08PM	Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) -13.97%
08:29AM	Scholar Rocks SMA Treatment Trials Show Promising Results (TipRanks)
06:43AM	Scholar Rock stocks skyrocket after SMA drug scores at Phase III (Clinical Trials Arena)
Oct-07-24 04:13PM	Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily) +361.99%
04:09PM	Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
03:23PM	Scholar Rock Shares Quadruple On Positive Drug-Study Results (The Wall Street Journal)
11:05AM	Scholar Rock stock surges on positive spinal muscular atrophy treatment data (Investing.com)
11:05AM	Scholar Rock Stock Quadruples on Positive Trial Data (Barrons.com)
09:41AM	Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily)
07:00AM	Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA) (Business Wire)
Sep-27-24 06:13AM	Scholar Rock Holding Corporation (NASDAQ:SRRK) Ranks High On The List Of Worst Falling Stocks To Buy Now (Insider Monkey)
Sep-13-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.48%
Sep-10-24 08:00AM	Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity (Business Wire) +5.89%
Sep-05-24 12:02AM	Scholar Rock Holding Corporation (SRRK): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-04-24 08:00AM	Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer (Business Wire)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Aug-16-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-15-24 04:32AM	Scholar Rocks apitegromab shows promise for non-ambulatory SMA (Clinical Trials Arena)
Aug-09-24 05:05AM	Q2 2024 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-08-24 07:00AM	Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress (Business Wire)
Jul-23-24 08:00AM	Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (Business Wire)
Jul-12-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-08-24 06:42PM	Scholar Rock Holding Corporation (SRRK): The Most Shorted Stock Loved by Analysts? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jun-24-24 07:00AM	Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal (Business Wire)
Jun-18-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 04:00PM	Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting (Business Wire)
May-28-24 08:00AM	Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
May-22-24 07:00AM	Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity (Business Wire)
May-20-24 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
May-17-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -12.78%
May-14-24 08:00AM	Scholar Rock to Host Investor Day on May 22, 2024 (Business Wire)
May-07-24 01:53PM	SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q1 2024 (InvestorPlace)
10:19AM	Scholar Rock Shares Fall on Wider-Than-Expected Q1 Loss (MT Newswires)
08:52AM	Scholar Rock Holding Corp (SRRK) Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com)
07:00AM	Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress (Business Wire)
Apr-24-24 06:33AM	3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains (InvestorPlace)
Apr-12-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.08%
Mar-20-24 05:31AM	Scholar Rock Holding Corp Reports Full Year 2023 Financial Results (GuruFocus.com) +8.58%
Mar-19-24 10:52PM	SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q4 2023 (InvestorPlace) +14.77%
07:00AM	Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress (Business Wire)
Mar-15-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.65%
08:18AM	Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks (Insider Monkey)
Feb-28-24 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Edward Myles	Former Officer	Jun 05 '25	Proposed Sale	32.50	19,599	636,967		Jun 05 04:57 PM
FLIER JEFFREY S.	Director	May 29 '25	Sale	29.73	6,075	180,584	24,070	May 30 04:32 PM
Burow Kristina	Director	May 29 '25	Sale	29.72	5,400	160,511	21,071	May 30 04:31 PM
Gilman Michael	Director	May 29 '25	Sale	29.72	3,375	100,304	55,216	May 30 04:31 PM
Brudnick Richard	Director	May 29 '25	Sale	29.72	6,075	180,531	15,057	May 30 04:31 PM
Reed Joshua	Director	May 29 '25	Sale	29.72	5,400	160,463	15,732	May 30 04:30 PM
Vaishnaw Akshay	President of R&D	May 29 '25	Sale	29.72	6,750	200,612	616,205	May 30 04:30 PM
Akshay Vaishnaw	Director	May 29 '25	Proposed Sale	29.66	6,750	200,205		May 29 04:51 PM
Joshua Reed	Director	May 29 '25	Proposed Sale	29.66	5,400	160,164		May 29 04:49 PM
Michael Gilman	Director	May 29 '25	Proposed Sale	29.66	3,375	100,103		May 29 04:46 PM
Jeffrey S. Flier	Director	May 29 '25	Proposed Sale	29.66	48,663	1,443,345		May 29 04:43 PM
Kristina Burow	Director	May 29 '25	Proposed Sale	29.66	5,400	160,164		May 29 04:39 PM
Richard Brudnick	Director	May 29 '25	Proposed Sale	29.66	6,075	180,185		May 29 04:35 PM
Sacco Tracey	Chief Commercial Officer	Apr 25 '25	Option Exercise	10.00	5,000	50,000	76,250	Apr 29 06:03 PM
Sacco Tracey	Chief Commercial Officer	Apr 25 '25	Sale	32.83	5,000	164,131	71,750	Apr 29 06:03 PM
Sacco Tracey	Chief Commercial Officer	Mar 24 '25	Option Exercise	10.00	5,000	50,000	78,250	Mar 25 07:39 PM
Sacco Tracey	Chief Commercial Officer	Mar 24 '25	Sale	33.08	6,500	215,014	71,750	Mar 25 07:39 PM
Moore Erin	Interim PFO and PAO	Mar 24 '25	Option Exercise	17.33	13,564	235,085	96,173	Mar 25 07:37 PM
Moore Erin	Interim PFO and PAO	Mar 24 '25	Sale	33.12	13,564	449,237	82,609	Mar 25 07:37 PM
Tracey Sacco	Affiliate	Mar 24 '25	Proposed Sale	33.00	41,500	1,369,500		Mar 24 07:20 PM
Peng Katie	Director	Mar 17 '25	Sale	34.42	1,006	34,627	30,319	Mar 19 05:00 PM
Katie Peng	Director	Mar 17 '25	Proposed Sale	34.60	4,037	139,680		Mar 17 06:50 PM
Myles Edward H	COO & CFO	Mar 10 '25	Option Exercise	13.60	112,897	1,535,083	253,637	Mar 12 07:06 PM
Myles Edward H	COO & CFO	Mar 10 '25	Sale	35.62	142,292	5,068,974	111,345	Mar 12 07:06 PM
Edward Myles	Officer	Mar 10 '25	Proposed Sale	35.00	161,890	5,666,150		Mar 10 04:15 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 19 '25	Option Exercise	10.19	48,308	492,186	179,594	Feb 20 07:55 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 19 '25	Sale	37.40	68,510	2,562,479	111,084	Feb 20 07:55 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 18 '25	Sale	36.83	4,135	152,288	131,286	Feb 20 07:55 PM
Parlavecchio Caryn	CHRO	Feb 18 '25	Sale	36.83	5,296	195,046	140,258	Feb 20 06:30 PM
Myles Edward H	COO & CFO	Feb 18 '25	Sale	36.83	7,809	287,598	140,740	Feb 20 06:18 PM
Ho Junlin	GENERAL COUNSEL	Feb 18 '25	Sale	36.83	5,742	211,472	189,295	Feb 20 05:53 PM
Backstrom Jay T.	CHIEF EXECUTIVE OFFICER	Feb 18 '25	Sale	36.83	18,372	676,622	311,991	Feb 20 05:41 PM
Mohammed Qatanani	Officer	Feb 19 '25	Proposed Sale	36.95	68,510	2,531,444		Feb 19 04:15 PM
Backstrom Jay T.	CHIEF EXECUTIVE OFFICER	Jan 16 '25	Sale	44.20	22,308	985,951	330,363	Jan 21 04:35 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Jan 16 '25	Sale	44.20	5,655	249,935	67,200	Jan 21 04:35 PM
Sacco Tracey	Chief Commercial Officer	Jan 16 '25	Sale	44.20	3,890	171,927	45,395	Jan 21 04:35 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 16 '25	Sale	44.20	7,347	324,717	135,421	Jan 21 04:35 PM
Parlavecchio Caryn	CHRO	Jan 16 '25	Sale	44.20	6,434	284,365	145,554	Jan 21 04:35 PM
Myles Edward H	COO & CFO	Jan 16 '25	Sale	44.20	12,539	554,189	148,549	Jan 21 04:35 PM
Ho Junlin	GENERAL COUNSEL	Jan 16 '25	Sale	44.20	9,039	399,498	195,037	Jan 21 04:35 PM
Invus Public Equities, L.P.	10% Owner	Dec 10 '24	Sale	41.65	1,600,000	66,640,000	9,250,005	Dec 12 04:39 PM
Invus Public Equities, L.P.	10% Owner	Nov 25 '24	Sale	38.49	409,433	15,757,639	10,850,005	Nov 27 04:31 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 25 '24	Option Exercise	8.59	6,375	54,761	79,230	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 22 '24	Option Exercise	8.59	2,145	18,426	75,000	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 25 '24	Sale	39.44	6,375	251,399	72,855	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 22 '24	Sale	30.01	2,145	64,372	72,855	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 11 '24	Option Exercise	8.59	2,105	18,082	74,960	Nov 13 04:40 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 11 '24	Sale	30.00	2,105	63,158	72,855	Nov 13 04:40 PM
Myles Edward H	COO & CFO	Oct 08 '24	Option Exercise	10.00	37,187	371,870	198,275	Oct 10 06:00 PM
Myles Edward H	COO & CFO	Oct 08 '24	Sale	34.90	37,187	1,297,659	161,088	Oct 10 06:00 PM
Myles Edward H	COO & CFO	Oct 07 '24	Sale	26.56	206,240	5,477,546	161,088	Oct 07 09:52 PM
Sacco Tracey	CHIEF COMMERCIAL OFFICER	Oct 07 '24	Option Exercise	10.00	30,000	300,000	79,285	Oct 07 09:03 PM
Sacco Tracey	CHIEF COMMERCIAL OFFICER	Oct 07 '24	Sale	25.62	30,000	768,677	49,285	Oct 07 09:03 PM
AKKARAJU SRINIVAS	Director	Oct 07 '24	Sale	29.25	1,175,713	34,385,672	5,612,896	Oct 07 08:55 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Oct 07 '24	Option Exercise	8.59	109,375	939,531	182,230	Oct 07 08:51 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Oct 07 '24	Sale	27.21	109,375	2,976,468	72,855	Oct 07 08:51 PM
AKKARAJU SRINIVAS	Director	Oct 07 '24	Proposed Sale	29.25	1,175,713	34,385,725		Oct 07 08:43 PM
Tracey Sacco	Officer	Oct 07 '24	Proposed Sale	25.62	30,000	768,693		Oct 07 04:20 PM
Jing Marantz	Officer	Oct 07 '24	Proposed Sale	32.50	120,000	3,900,000		Oct 07 04:18 PM
Edward Myles	Officer	Oct 07 '24	Proposed Sale	32.50	243,427	7,911,378		Oct 07 04:16 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Sep 16 '24	Sale	8.58	1,936	16,611	142,768	Sep 19 08:15 AM
Parlavecchio Caryn	CHRO	Aug 16 '24	Sale	9.33	1,451	13,538	151,988	Aug 19 05:00 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jun 17 '24	Sale	8.98	2,315	20,800	144,704	Jun 18 05:56 PM
Parlavecchio Caryn	CHRO	Jun 17 '24	Sale	8.98	4,305	38,680	153,439	Jun 18 05:55 PM
Myles Edward H	COO & CFO	Jun 17 '24	Sale	8.98	9,458	84,978	201,518	Jun 18 05:54 PM
Ho Junlin	GENERAL COUNSEL	Jun 17 '24	Sale	8.98	4,695	42,183	204,076	Jun 18 05:53 PM

Open in Screener

PRME

Prime Medicine Inc

Jun 06 • 04:00PM ET

1.69

Dollar change +0.33
Percentage change 24.26	%

Healthcare • Biotechnology • USA • NASD

PRME Prime Medicine Inc daily Stock Chart

Peers: CRSP NTLA EDIT BEAM ALLO VERV DNLI IGMS PSTX SANA

| Held by: VTI ARKG IWM VXF IWO VTWO IBB SCHA VHT XDNA

Index	RUT	P/E	-	EPS (ttm)	-1.66	Insider Own	60.60%	Shs Outstand	131.16M	Perf Week	43.22%
Market Cap	221.89M	Forward P/E	-	EPS next Y	-1.00	Insider Trans	0.31%	Shs Float	51.73M	Perf Month	19.01%
Income	-202.01M	PEG	-	EPS next Q	-0.36	Inst Own	28.66%	Short Float	34.22%	Perf Quarter	-29.58%
Sales	3.85M	P/S	57.63	EPS this Y	23.33%	Inst Trans	-6.36%	Short Ratio	9.49	Perf Half Y	-46.01%
Book/sh	0.82	P/B	2.07	EPS next Y	20.83%	ROA	-63.17%	Short Interest	17.70M	Perf Year	-73.80%
Cash/sh	1.10	P/C	1.54	EPS next 5Y	18.30%	ROE	-115.21%	52W Range	1.11 - 8.14	Perf YTD	-42.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-124.13%	ROI	-91.32%	52W High	-79.25%	Beta	1.50
Dividend TTM	-	Quick Ratio	4.78	Sales past 5Y	-	Gross Margin	-69.34%	52W Low	52.25%	ATR (14)	0.16
Dividend Ex-Date	Sep 10, 2019	Current Ratio	4.78	EPS Y/Y TTM	22.37%	Oper. Margin	-5369.68%	RSI (14)	62.87	Volatility	9.96% 9.64%
Employees	214	Debt/Eq	1.13	Sales Y/Y TTM	550.76%	Profit Margin	-5252.50%	Recom	1.73	Target Price	7.69
Option/Short	Yes / Yes	LT Debt/Eq	1.07	EPS Q/Q	9.47%	Payout	-	Rel Volume	2.65	Prev Close	1.36
Sales Surprise	-67.60%	EPS Surprise	-27.59%	Sales Q/Q	146.02%	Earnings	May 08 BMO	Avg Volume	1.87M	Price	1.69
SMA20	29.83%	SMA50	16.89%	SMA200	-39.51%	Trades		Volume	4,950,106	Change	24.26%

Date	Action	Analyst	Rating Change	Price Target Change
May-27-25	Downgrade	Citigroup	Buy → Neutral	$1.50
May-20-25	Downgrade	JP Morgan	Overweight → Neutral
May-20-25	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-10-24	Initiated	JMP Securities	Mkt Outperform	$10
May-20-24	Initiated	H.C. Wainwright	Buy	$10
May-16-24	Upgrade	Citigroup	Neutral → Buy	$10
Apr-22-24	Initiated	Chardan Capital Markets	Buy	$17
Apr-08-24	Initiated	TD Cowen	Buy
Apr-03-24	Initiated	Wedbush	Outperform	$12
Jan-16-24	Downgrade	Stifel	Buy → Hold	$18 → $9
Dec-08-23	Initiated	Citigroup	Neutral	$10
Oct-09-23	Initiated	BMO Capital Markets	Outperform	$19
Jul-31-23	Initiated	Guggenheim	Buy	$24
Apr-18-23	Initiated	Stifel	Buy	$18
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight	$23
Nov-14-22	Initiated	JP Morgan	Overweight	$27
Nov-14-22	Initiated	Jefferies	Buy	$25
Nov-14-22	Initiated	Goldman	Neutral	$22

Show Previous Ratings

May-29-25 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-27-25 02:24PM	Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty (Insider Monkey)
May-22-25 12:35PM	Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More (Zacks) +5.58%
May-19-25 08:31AM	Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition (GlobeNewswire) -16.04%
08:30AM	Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease (GlobeNewswire)
08:28AM	Loading…
08:28AM	Prime Medicine claims proof of concept, but lays off staff in pivot (BioPharma Dive)
May-08-25 09:25AM	Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.04%
08:00AM	Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
May-07-25 05:10PM	Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.77%
May-05-25 08:25AM	Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.55%
Apr-25-25 10:51AM	Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 (Seeking Alpha)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -10.30%
Mar-20-25 06:48PM	Why Prime Medicine Stock Was Climbing Higher This Week (Motley Fool)
Mar-19-25 02:56PM	Why Prime Medicine Stock Is Soaring Today (Fool) +13.64%
Mar-18-25 08:09AM	Prime sets sights on liver, lung disease as next target for its gene editing tech (BioPharma Dive)
07:00AM	Loading…
07:00AM	Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Feb-28-25 08:00AM	Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-24-25 08:00AM	Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-07-25 08:00AM	Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-24 01:00PM	Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? (Insider Monkey) +5.04%
Dec-30-24 02:46PM	Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-29-24 06:25AM	Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Nov-12-24 04:00PM	Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.33%
Nov-06-24 04:00PM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 10:00AM	12 High-Growth Stocks That Could Deliver Parabolic Returns (Motley Fool)
Oct-24-24 08:00AM	Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress (GlobeNewswire) +5.26%
Oct-16-24 09:45AM	Why I Keep Buying These 14 Incredible Growth Stocks (Motley Fool) +5.04%
Oct-15-24 08:00AM	Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings (GlobeNewswire)
Oct-01-24 09:33AM	BMS and Prime ink potential $3.5bn deal to develop T cell therapies (Pharmaceutical Technology) -10.85%
Sep-30-24 06:08PM	Why Prime Medicine Stock Soared Nearly 12% Higher on Monday (Motley Fool) +11.85%
08:38AM	Loading…
08:38AM	Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline (Benzinga)
07:01AM	Prime Medicine Unveils Strategically Focused Pipeline (GlobeNewswire)
07:00AM	Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies (GlobeNewswire)
06:30AM	Prime to narrow gene editing research as it strikes deal with Bristol Myers (BioPharma Dive)
Aug-28-24 08:15AM	2 Growth Stocks That Could Make You Richer (Motley Fool)
08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 08:00AM	Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-31-24 01:53PM	Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings? (Zacks)
Jul-19-24 10:00AM	Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait? (Zacks)
Jul-08-24 05:44PM	Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
May-30-24 09:55AM	Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade (Zacks)
08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
May-29-24 06:30AM	If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names (InvestorPlace)
May-25-24 04:10AM	Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio (Motley Fool)
May-20-24 09:32PM	Cathie Wood Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks) +6.36% +6.64%
09:33AM	HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target (MT Newswires)
May-17-24 06:27AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024 (InvestorPlace)
06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace)
May-16-24 07:14AM	Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target (MT Newswires)
May-14-24 09:55AM	Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect? (Zacks)
May-13-24 11:12AM	JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating (MT Newswires) +14.44%
08:00AM	Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-12-24 03:00AM	Alphabet Bought Up Two Slumping Stocks (Barrons.com)
May-10-24 02:23PM	Prime Medicine Inc (PRME) Q1 2024 Earnings: Navigates Through Challenges with Strategic Developments (GuruFocus.com)
01:53PM	PRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-08-24 08:00AM	Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
May-03-24 12:00PM	What Makes Prime Medicine, Inc. (PRME) a New Buy Stock (Zacks)
May-01-24 08:00AM	Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference (GlobeNewswire) +7.11%
Apr-30-24 06:01AM	Prime Medicine gets green light for trials of first-ever prime editing drug (Clinical Trials Arena)
Apr-29-24 10:12AM	Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance (MT Newswires) +9.83%
07:35AM	Prime gets FDA green light to begin first trial test of prime editing (BioPharma Dive)
07:33AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
07:00AM	Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
Apr-23-24 08:00AM	Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings (GlobeNewswire)
Mar-27-24 08:45AM	2 Magnificent Growth Stocks With Room to Run (Motley Fool)
Mar-14-24 02:44PM	Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging (InvestorPlace) -13.18%
Mar-01-24 02:00PM	Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too? (InvestorPlace)
08:00AM	Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) -5.99%
Feb-28-24 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-20-24 04:01PM	Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.08% +5.73%
Feb-14-24 11:50PM	Prime Medicine Announces Pricing of Upsized Public Offering (GlobeNewswire) +13.62%
04:05PM	Prime Medicine Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-01-24 08:00AM	Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire) +5.67%
Jan-25-24 08:00AM	Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE Prime Editors for Cystic Fibrosis (GlobeNewswire)
Jan-09-24 06:21PM	Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should Know (Zacks)
Jan-05-24 05:00PM	Prime Medicine and Myeloid Therapeutics Announce Settlement of Pending Disputes (PR Newswire)
08:00AM	Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer (GlobeNewswire)
Jan-02-24 08:00AM	Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-23 10:30AM	Better Growth Stock: Archer Aviation or Prime Medicine? (Motley Fool) +6.73%
Nov-30-23 07:45AM	1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years (Motley Fool)
Nov-08-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire) -9.75%
Nov-03-23 04:01PM	Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) +17.65%
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-27-23 06:00AM	Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b (GlobeNewswire) -6.60%
Oct-24-23 07:30AM	Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases (GlobeNewswire)
05:04AM	The Bull Market Can Continue to Roll On; BMOs Brian Belski Predicts Further Gains for Stocks Here Are 3 Names to Play That Bullish Sentiment (TipRanks)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-17-23 08:00AM	Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences (GlobeNewswire) +10.00%
Oct-09-23 09:33AM	Oracle upgraded, Spotify downgraded: Wall Street's top analyst calls (The Fly)
Sep-19-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-31-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-07-23 04:01PM	Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -8.66%
Jul-25-23 07:45AM	2 Cathie Wood Stocks That Could Be Hidden Gems (Motley Fool)
Jun-29-23 08:46AM	We're Hopeful That Prime Medicine (NASDAQ:PRME) Will Use Its Cash Wisely (Simply Wall St.)
Jun-22-23 08:00AM	Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome (GlobeNewswire)
Jun-02-23 10:15AM	Cathie Wood Goes Bargain-Hunting: 3 Stocks She Just Bought (Motley Fool) +9.15%
May-31-23 08:00AM	Prime Medicine to Present at Investor Conferences in June (GlobeNewswire)

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brudnick Richard	Chief Business Officer	May 20 '25	Buy	1.19	20,000	23,790	20,000	May 22 04:22 PM
LEE ANN L.	Chief Technical Officer	May 21 '25	Buy	1.13	100,000	113,000	100,000	May 22 04:21 PM
Reine Allan	Chief Executive Officer	May 21 '25	Buy	1.18	125,000	147,150	125,000	May 22 04:18 PM

SRRK

Scholar Rock Holding Corp

PRME

Prime Medicine Inc

Upgrade your FINVIZ experience